According to our latest study on "Respiratory Inhalers Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Product Type, Technology, and Disease Indication," the market is expected to grow from US$ 31,144.56 million in 2022 to US$ 43,446.19 million by 2028; it is estimated to record a CAGR of 5.7% from 2022 to 2028. The rising cases of respiratory disorders and growing adoption of generic inhalers are contributing to the overall respiratory inhalers market growth. Additionally, increasing product development activities is likely to emerge as a significant trend in the respiratory inhalers market during the forecast period. However, lack of early diagnosis and high cost of inhalers are a few factors hampering the respiratory inhalers market growth.

Increasing Product Development Activities to Boost Respiratory Inhalers Market Growth During Forecast Period

With new medical knowledge and effective medicines, treatment with a wide range of asthma inhalers continues to advance. Rising use of ventilator combination therapies and increasing investments by major players in developing sophisticated ventilator inhalers are boosting the demand for respiratory inhalers. In addition to the numerous advantages of the device such as portability, convenience, and effectiveness, the growing number of product approvals and developments is expected to strengthen the demand for respiratory inhalers in the coming years. A few of the major developments and approvals are listed below:

• In November 2022, AstraZeneca partnered with Avillion to develop PT027, an asthma rescue inhaler. PT027 is a pressurized metered-dose inhaler that delivers a fixed dose of two combined asthma medications: albuterol—a short-acting beta2-agonist and budesonide, an anti-inflammatory inhaled corticosteroid.
• In December 2020, OMRON launched WheezeScan, the world’s first wheeze detection device to help children with asthma, which is a crucial breakthrough in the field of pediatric asthma management. WheezeScan helps parents of young children detect wheezing—a clear indicator of an upcoming asthma attack-—and act accordingly.
• In December 2020, AireHealth, an innovative digital health company, received 510(k) clearance for its connected nebulizer. The device is a portable, electronic vibrating mesh nebulizer designed to nebulize liquid medications for inhalation by a patient in and out of the home and will be marketed under the brand name VitalMed.
• In October 2020, Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., declared the product availability of Aermony RespiClick in Canada. The inhaler is indicated for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older and is offered in a simple-to-use inhaler.
• In September 2020, Teva Respiratory, LLC., a US affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of AirDuo Digihaler inhalation powder and ArmonAir Digihaler inhalation powder, two digital maintenance inhalers for patients with asthma.
• In September 2020, GlaxoSmithKline plc and Innoviva, Inc. received FDA approval for Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US.
• In July 2020, Novartis received the European Commission (EC) approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside treatment of uncontrolled asthma in the EU.
• In May 2020, Propeller Health, a leading digital health company dedicated to the management of asthma and COPD, received FDA clearance to introduce its connected platform to AstraZeneca's Symbicort. The platform helps digitize the treatment of asthma and chronic obstructive pulmonary disease (COPD)
• In January 2020, FDA approved the CapMedic smart inhaler cap from Cognita Labs, which is capable of transmitting signals to patients to use inhalers correctly.

Thus, such increasing advancements by various market players and product approvals are likely to catalyze the growth of the global respiratory inhalers market during the forecast period.

AstraZeneca Plc; Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH; Cipla Ltd.; GSK Plc; Koninklijke Philips NV; OMRON Corp; PARI Respiratory Equipment, Inc.; Teva Pharmaceutical Industries Ltd.; and OPKO Health, Inc. are among the leading companies operating in the respiratory inhalers market.

The report segments the respiratory inhalers market as follows:

The respiratory inhalers market is segmented on the basis of product type, technology, disease indication, and geography. Based on product type, the respiratory inhalers market is segmented nebulizers, metered dose inhalers (MDI), and dry powder inhalers. The dry powder inhalers segment is further bifurcated into multi-dose dry powder inhalers and single-dose dry powder inhalers. The metered dose inhalers (MDI) segment is further divided into pressured metered dose inhalers and connected metered dose inhalers. The nebulizers segment is subsegmented into compressed air nebulizers, mesh air nebulizers, and ultrasonic air nebulizers. Based on technology, the respiratory inhalers market is bifurcated into manually operated inhalers and digitally operated inhalers. Based on disease indication, the respiratory inhalers market is segmented into asthma, COPD, pulmonary arterial hypertension, and others. Based on geography, the respiratory inhalers market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Netherlands, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, Thailand, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com